Atrium acquires Douglas Laboratories Canada
Atrium Biotechnologies Inc. announced the acquisition of the assets of London, Ontario based Douglas Laboratories Canada ("DL Canada"). DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million.
"This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market not only for the Douglas Laboratories brand but also for the Pure Encapsulations brand which is not currently being sold in Canada. This acquisition further reinforces our current leadership position in North America and marks another step in our strategy to control access to markets and build solid organic growth for our brands," stated Richard Bordeleau, President of Atrium's Health & Nutrition Division.
In addition, Atrium will be able to benefit from the expertise and support of DL Canada's current management and staff who are staying on to ensure the successful integration and to sustain its growth.
Most read news
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.